Showing results (1221-1230 of 1,246) with videos related to

Sort By:
Pageof 125
Plos Medicine|June 24, 2024
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trialStephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Frontiers in Microbiology|July 29, 2022
Microbiome Research as an Effective Driver of Success Stories in Agrifood Systems - A Selection of Case StudiesRocío Olmo, Stefanie Urimare Wetzels, Jaderson Silveira Leite Armanhi, et al.
Nature|December 20, 2013
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIVMario Roederer, Brandon F Keele, Stephen D Schmidt, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Nature|September 28, 2018
Combination therapy with anti-HIV-1 antibodies maintains viral suppressionPilar Mendoza, Henning Gruell, Lilian Nogueira, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Emerging Microbes & Infections|April 7, 2025
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trialsZoe Moodie, Shuying Sue Li, Elena E Giorgi, et al.
The Cochrane Database of Systematic Reviews|March 25, 2025
Audit and feedback: effects on professional practiceNoah Ivers, Sharlini Yogasingam, Meagan Lacroix, et al.
Pageof 125